Corbus Pharmaceuticals Reports Last Subject Visit in Phase IIb Study of Lenabasum for Treatment of Cystic Fibrosis

Corbus Pharmaceuticals Holdings, Inc. announced that the last subject completed their final visit in the company’s Phase IIb JBT101-CF-002 trial of lenabasum for the treatment of cystic fibrosis.
[Corbus Pharmaceuticals Holdings, Inc]
Press Release
Bookmark

No account yet? Register

0
Share

It’s a Nightmare.’ How Brazilian Scientists Became Ensnared in Chloroquine Politics

In April, a published study showed chloroquine could increase mortality in COVID-19 patients. Since then, they have been accused of poisoning their patients with a high dose of chloroquine just to give the drug—praised by US President Donald Trump and his Brazilian counterpart Jair Bolsonaro—a bad name.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

0
Share

‘Has it peaked? I don’t know.’ NIH Official Details Foreign Influence Probe

Four years after the National Institutes of Health (NIH) began to investigate grantees who it believed had failed to disclose their ties to foreign governments, officials still don’t know the full extent of the problem.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

0
Share

Virtual Lab Tours for Recruitment and Outreach

Virtual lab tours are not new, but they have never been as common as in-person lab tours. However, the pandemic has generated strong incentives for formerly in-person lab tours to go online.
[The Scientist]
Press Release
Bookmark

No account yet? Register

0
Share

Acceleration in New COVID-19 Cases in Some US States Causes Alarm

The growth in the number of COVID-19 cases is accelerating substantially in more than one-quarter of US states, as federal and local governments grapple with how to ease lockdown measures brought in to help slow the pandemic.
[The Scientist]
Press Release
Bookmark

No account yet? Register

0
Share

Top US Health Officials Say They Were Never Told to Slow Down COVID-19 Testing, Contradicting Trump

Four key government health care officials said Tuesday that despite recent remarks from President Trump, they were never ordered to “slow down” diagnostic testing for Covid-19.
[STAT News]
Press Release
Bookmark

No account yet? Register

0
Share

Trump to Suspend New Visas for Foreign Scholars

With a proclamation issued on Monday, US President Donald Trump extended and expanded immigration restrictions to limit the entry of foreign workers to the United States. The move set off ripples of alarm among scientists and drew fire from experts concerned about the future of US science.
[Nature News]
Press Release
Bookmark

No account yet? Register

0
Share

Ultragenyx and Kyowa Kirin Announce US FDA Approval of Crysvita® (Burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)

Ultragenyx Pharmaceutical, Inc. and Kyowa Kirin Co., Ltd. announced that the FDA has approved Crysvita® for the treatment of fibroblast growth factor 23-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric patients two years of age and older.
[Ultragenyx Pharmaceutical, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

IMBRUVICA® (Ibrutinib) Seeks to Expand US Label with Long-Term Data in Waldenström’s Macroglobulinemia (WM)

AbbVie announced that the FDA will review a supplemental New Drug Application (sNDA) for IMBRUVICA® in combination with rituximab for the treatment of WM, a rare and incurable type of non-Hodgkin’s lymphoma.
[AbbVie Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Marker Therapeutics Receives USAN Approval for “Zelenoleucel” as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia

Marker Therapeutics, Inc. announced that the United States Adopted Names Council has approved “zelenoleucel” as the nonproprietary name for MT-401, a multi-tumor-associated antigen-specific T cell product candidate for the treatment of patients with acute myeloid leukemia following allogeneic stem cell transplant in both adjuvant and active disease settings.
[Marker Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Chi-Med Announces Fruquintinib Granted US FDA Fast Track Designation for Metastatic Colorectal Cancer

Hutchison China MediTech Limited announced that the FDA has granted Fast Track Designation for the development of fruquintinib, for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if RAS wild-type, an anti-epidermal growth factor receptor therapy.
[Hutchison China MediTech Limited ]
Press Release
Bookmark

No account yet? Register

0
Share
Share